China Isotope & Radiation (HKSE:01763) Ending Cash Position : HK$2,599 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation Ending Cash Position?

China Isotope & Radiation's Ending Cash Position for the quarter that ended in Dec. 2023 was HK$2,599 Mil.

China Isotope & Radiation's quarterly Ending Cash Position declined from Dec. 2022 (HK$2,498 Mil) to Jun. 2023 (HK$1,811 Mil) but then increased from Jun. 2023 (HK$1,811 Mil) to Dec. 2023 (HK$2,599 Mil).

China Isotope & Radiation's annual Ending Cash Position declined from Dec. 2021 (HK$2,622 Mil) to Dec. 2022 (HK$2,498 Mil) but then increased from Dec. 2022 (HK$2,498 Mil) to Dec. 2023 (HK$2,599 Mil).

China Isotope & Radiation Ending Cash Position Historical Data

The historical data trend for China Isotope & Radiation's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation Ending Cash Position Chart

China Isotope & Radiation Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

2,938.01

2,787.67

2,622.14

2,497.90

2,599.32

China Isotope & Radiation Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial											2,622.14	2,276.77	2,497.90	1,810.71	2,599.32

China Isotope & Radiation Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

China Isotope & Radiation's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2446.597	+	152.724
	=	2,599

China Isotope & Radiation's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1844.648	+	754.673
	=	2,599

China Isotope & Radiation Ending Cash Position Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

China Isotope & Radiation (HKSE:01763) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089

Website

https://www.china-isotope.com

China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

Executives

Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Li Hongbo	2201 Interest of corporation controlled by you
Lianwen Ltd	2101 Beneficial owner
Invesco Advisers, Inc.	2102 Investment manager
The Bank Of New York Mellon Corporation	2201 Interest of corporation controlled by you
Invesco Hong Kong Limited	2102 Investment manager
Invesco Corporate Class Inc.	2106 Person having a security interest in shares
M&g Plc	2201 Interest of corporation controlled by you
Shanghai Industrial Holdings Limited	2201 Interest of corporation controlled by you
Shanghai Industrial Investment (holdings) Company Limited	2201 Interest of corporation controlled by you
Serenity Investment Master Fund Limited	2101 Beneficial owner
Serenity Capital Management, Ltd.	2102 Investment manager
Shanghai Pharmaceuticals Holding Co., Ltd.	2201 Interest of corporation controlled by you
S.i. Infrastructure Holdings Limited	2201 Interest of corporation controlled by you

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines